Molecular Formula | C22H24N4O4 |
Molar Mass | 408.45 |
Density | 1.36 |
Boling Point | 635.5±65.0 °C(Predicted) |
Solubility | DMSO 82 mg/mL Water <1 mg/mL Ethanol 10 mg/mL |
pKa | 3.90±0.50(Predicted) |
Storage Condition | -20℃ |
Use | A PI3K inhibitor and antiplatelet agent. |
In vitro study | AZD6482 is a PI3Kβ inhibitor with an IC50 of 21 nM, however, AZD6482 also inhibits PI3Kα,γ, and δ with an IC50 of 80 nM to 1.4 μm, which is significantly greater than its ().-Much lower for the imprinted isomer (S-form). AZD6482 is an antiplatelet agent that inhibits activated platelet adhesion/aggregation and promotes platelet deaggregation with an IC50 of 6 nM in washed platelet aggregation (WPA) experiments. Furthermore, AZD6482 targets PI3Kβ, specifically inhibiting thrombosis without affecting normal hemostasis. Therefore, AZD6482 is used as an antithrombotic agent for the Prevention of thrombotic diseases. AZD6482 is a PI3Kβ inhibitor with an IC50 of 21 nM, however, AZD6482 also inhibits PI3Kα,γ, and δ with an IC50 of 80 nM to 1.4 μm, which is significantly greater than its ()-Much lower for the imprinted isomer (S-form). AZD6482 is an antiplatelet agent that inhibits activated platelet adhesion/aggregation and promotes platelet deaggregation with an IC50 of 6 nM in washed platelet aggregation (WPA) experiments. Furthermore, AZD6482 targets PI3Kβ, specifically inhibiting thrombosis without affecting normal hemostasis. Therefore, AZD6482 is used as an antithrombotic agent for the Prevention of thrombotic diseases. |
biological activity | AZD6482 is a PI3Kβ inhibitor with an IC50 of 10 nM, acting on PI3Kβ than on PI3Kδ, the PI3Kα and PI3Kγ selectivities were 8,87 and 109-fold higher, respectively. Phase 1. AZD6482 (1.193) is a PI3Kβ inhibitor with an IC50 of 10 nM in cell-free assay. PI3Kβ is more selective for PI3Kα and PI3Kγ than PI3Kδ, 87 and 109 times. Phase 1. |
in vitro study | AZD6482 is a PI3Kβ inhibitor with an IC50 of 21 nM, however, AZD6482 also inhibits PI3Kα, and δ, IC50 of 80 nM to 1.4 μm, significantly lower than its ()-p-isomer (S-form). AZD6482 is an antiplatelet agent that inhibits activated platelet adhesion/aggregation and promotes platelet deaggregation with an IC50 of 6 nM in washed platelet aggregation (WPA) experiments. Furthermore, AZD6482 targets PI3Kβ, specifically inhibiting thrombosis without affecting normal hemostasis. Therefore, AZD6482 is used as an antithrombotic agent for the Prevention of thrombotic diseases. AZD6482 is a PI3Kβ inhibitor with an IC50 of 21 nM, however, AZD6482 also inhibits PI3Kα,γ, and δ with an IC50 of 80 nM to 1.4 μm, which is significantly greater than its ()-Much lower for the imprinted isomer (S-form). AZD6482 is an antiplatelet agent that inhibits activated platelet adhesion/aggregation and promotes platelet deaggregation with an IC50 of 6 nM in washed platelet aggregation (WPA) experiments. Furthermore, AZD6482 targets PI3Kβ, specifically inhibiting thrombosis without affecting normal hemostasis. Therefore, AZD6482 is used as an antithrombotic agent for the Prevention of thrombotic diseases. |
characteristics | AZD6482 is a PI3Kβ inhibitor that acts as an antiplatelet and antithrombotic agent. |
Target | TargetValue PI3Kβ (Cell-free assay) 10 nM PI3Kδ (Cell-free assay) 80 nM DNA-PK (Cell-free assay) 420 nM PI3Kα (Cell-free assay) 870 nM |
Target | Value |
PI3Kβ (Cell-free assay) | 10 nM |
PI3Kδ (Cell-free assay) | 80 nM |
DNA-PK (Cell-free assay) | 420 nM |
PI3Kα (Cell-free assay) | 870 nM |